Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD for Liver Fat in Fatty Liver Disease
NCT01284634Phase 2Completed
- Sponsor
- GW Pharmaceuticals
- Start
- May 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in fatty liver disease (FLD), sponsored by GW Pharmaceuticals. Started May 2011; status: completed.
02
Drugs
cannabidiol
03
Conditions
fatty liver disease (FLD)
Beyond the preview
Go deeper on NCT01284634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01284634.